Veltassa logo
Prescribing Information
Adverse Event Reporting
Search

Main navigation

  • What is Hyperkalaemia?
  • HK Challenge in CKD
  • HK Challenge in HF
  • About Veltassa
  • Clinical Experience
  • Resources
Search

Report adverse events:

Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com

Send email
Privacy Notice

Privacy Notice

Privacy notice for subscriptions to receive electronic communications from Vifor Pharma

We, Vifor Pharma Management AG, Flughofstrasse 61, 8152 Glattbrugg, Switzerland, are asking for your consent for us and other Vifor Pharma Group companies (together the “Vifor Pharma Group”) to send you the types of information specified in the subscription form, by the electronic channels you have selected in that form. We will only send you information which we believe could be of interest to you.

Who will have access to your electronic contact details?

We may share your electronic contact details with other Vifor Pharma Group companies to enable them to send you information electronically. Information about the companies of the Vifor Pharma Group is available at: https://www.viforpharma.com/en/about-vifor-pharma/global-presence. We may also share your contact details with third party service providers so that they can assist Vifor Pharma Group companies to provide such information to you. We may review the list of subscribers from time to time to help us to understand how to improve our website and the information we provide.

Some Vifor Pharma Group companies and third party service providers who will receive access to your contact details are in the European Economic Area or Switzerland, which are territories providing adequate protection for personal data. Access may also be provided to Vifor Pharma Group companies and/or third party service providers outside those territories. In those cases, we will ensure that adequate safeguards such as the official EU Standard Contractual Clauses are in place if required by law. You may request a copy of the relevant safeguards by contacting us as specified below.

We gather statistics on interactions with our emails and other electronic communications to help us improve them and ensure that they are useful and relevant.

For how long will your electronic contact details be kept?

We will not store your electronic contact details for longer than 5 years after our last interaction with you.

What are your rights?

You are not under any obligation to consent to receive electronic communications from us.

If you give your consent you are entitled to withdraw it at any time or to change the electronic channels by which you agree to receive electronic communications, by contacting us, the “Data Controller”, in any of the following ways:

  • following the instructions to unsubscribe from electronic communications which are specified in our communications; or
  • sending an email to the Vifor Pharma Group’s Data Protection Officer: GroupDPO@viforpharma.com

If you deny your consent, or subsequently withdraw it, the only consequence will be that you will not receive unsolicited electronic communications from the Vifor Pharma Group.

You have certain rights in respect of your contact details and other personal data such as a right of access, correction, restriction of use, erasure, and portability. If you wish to exercise your rights, or if you have questions about our use of your contact details, please contact us as specified above. You are also entitled to complain to a supervisory authority.

Our representative in the European Union is Vifor Pharma Deutschland GmbH, Baierbrunner Strasse 29, D-81379 Munich, Germany (dataprivacy_EEArep@viforpharma.com).

Version: 28.07.2020

Contact a Vifor medical representative

To learn more about hyperkalaemia management with Veltassa®, please contact us.

Contact us
logo

Address

Veltassa

Rechenstrasse 37,
9014 St. Gallen,
Switzerland

Stay in touch

Keep up to date on social media or
Contact us with any other Information

T: +41 (0) 58 851 8000
F: +41 (0) 58 851 8001
medinfo@viforpharma.com

Sign up for alerts

Be notified of any news, reports or
updates straight to your email address

 Sign up and get the latest news

Footer

  • What is Hyperkalaemia?
    • K+ Homeostasis is critical
    • What causes hyperkalaemia?
    • HK is a serious medical condition
    • CKD and HF patients are at Risk of HK
  • HK Challenge in CKD
    • RAASI therapy is vital
    • HK Risk is exacerbated by RAASI
    • HK leads to suboptimal RAASI use
    • Current treatment options are limited
  • HK Challenge in HF
    • RAASI therapy is vital
    • HK Risk is exacerbated by RAASI
    • HK leads to suboptimal RAASI use
    • Current treatment options are limited
  • About Veltassa
    • What is Veltassa
    • Mechanism of action of Veltassa
    • Easy to use
  • Clinical Experience
    • Reliable K+ Control
    • RAASI enablement
    • Favourable safety and tolerability
    • Clinical programme
  • Resources
    • For you
    • For your patients

The information and materials for Veltassa contained in this website were prepared based on the EU SmPC. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd, a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and 0M Pharma. For more information about Vifor Pharma, please visit www.viforpharma.com

This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site’s accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2019 Vifor Fresenius Medical Care Renal Pharma

Terms of use Privacy policy Cookie policy Prescribing information COOKIE SETTINGS
HQ-PAT-2000046 | Date of preparation: December 2020